source
- Biogen's tau-targeting Alzheimer's drug shows cognitive slowing in mid-stage trialBiogen reported results from its mid-stage "Celia" trial testing the experimental tau-targeting antibody BIIB080 in patients with early Alzheimer's disease. The study compared three dose levels of…
- Draig Therapeutics secures $65M Series B to advance brain-drug trialsDraig Therapeutics announced a $65 million Series B financing led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace and other investors. The capital will fund…